The MRC’s first decade of translational research funding has led to £1.1bn private sector investment and new therapies for patients.
A new report has found that the Medical Research Council’s (MRC) funding schemes for translational research have boosted the UK’s life sciences industry since they were introduced in 2008. More than £530 million of new translational research funding since then has led to MRC-linked spinouts securing £1.1 billion in private sector investment and delivering health benefits, such as new gene therapies and medical devices.
Specific funding schemes for translational research were introduced by the MRC in 2008 as a response to recommendations arising from the Government’s 2006 Cooksey Review of UK health research funding. The review highlighted that not enough research was progressing from the bench to the bedside – through the so-called ‘valley of death’.